On August 23, 2024, Jane Henderson, Chief Financial Officer of Apogee Therapeutics Inc (NASDAQ:APGE), sold 6,000 shares of the company at a price of $48.26 per share. The transaction was documented in an SEC filing. Following this sale, the insider now owns 200,871 shares of Apogee Therapeutics Inc. Apogee Therapeutics Inc. is engaged in the […]